处方安非他命与精神病及躁狂发作风险
该病例对照研究利用电子健康记录比较过去一个月处方安非他命暴露与精神病或躁狂发作的比值比,纳入1374例病例和2748例对照,发现使用安非他命者精神病和躁狂发作的比值增高(调整比值比=2.68,95%CI=1.90-3.77),高剂量(>30 mg右旋安非他命当量)与5.28倍增高的比值相关,而哌甲酯使用与比值增高无关联(调整比值比=0.91,95%CI=0.54-1.55)。
要点
- 过去一个月使用处方安非他命者精神病和躁狂发作的比值较未使用者增高(调整比值比=2.68,95%CI=1.90-3.77)。
- 高剂量安非他命(>30 mg右旋安非他命当量)与5.28倍增高的精神病或躁狂发作比值相关。
- 过去一个月使用哌甲酯与精神病或躁狂发作比值增高无关联(调整比值比=0.91,95%CI=0.54-1.55)。
核心结论
- 研究结果提示,处方高剂量安非他命时应谨慎,并定期筛查精神病或躁狂症状。
研究设计与样本
- 采用电子健康记录的病例对照研究,比较过去一个月处方安非他命暴露与精神病或躁狂发作的比值比。
- 病例为2005年至2019年在麦克莱恩医院因精神病或躁狂发作住院的16-35岁患者,对照为因其他原因首次精神科住院的患者(最常见为抑郁和/或焦虑)。
- 安非他命剂量转换为右旋安非他命当量并分为三分位数。
- 次要分析评估哌甲酯使用与精神病或躁狂发作的比值比。
主要发现
- 共纳入1374例病例和2748例对照。
- 过去一个月使用处方安非他命者精神病和躁狂发作的比值较未使用者增高(调整比值比=2.68,95%CI=1.90-3.77)。
- 观察到剂量-反应关系;高剂量安非他命(>30 mg右旋安非他命当量)与5.28倍增高的精神病或躁狂发作比值相关。
- 过去一个月使用哌甲酯与精神病或躁狂发作比值增高无关联(调整比值比=0.91,95%CI=0.54-1.55)。
临床怎么用
- 作者认为,处方高剂量安非他命时应谨慎,并定期筛查精神病或躁狂症状。
局限性
- 使用住院对照排除了疾病较轻的个体,导致选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Amphetamine prescribing has increased in the United States in recent years. Previous research identified an increased risk of incident psychosis with prescription amphetamines. The purpose of this study was to examine the impact of dose levels of prescription amphetamines on the risk of this rare but serious adverse outcome. METHODS: A case-control study using electronic health records was conducted to compare the odds of incident psychosis or mania with past-month exposure to prescription amphetamines. Case subjects were patients ages 16-35 hospitalized at McLean Hospital for incident psychosis or mania between 2005 and 2019. Control subjects were patients with an initial psychiatric hospitalization for other reasons, most commonly depression and/or anxiety. Amphetamine doses were converted to dextroamphetamine equivalents and divided into terciles. Secondary analyses evaluated the odds of psychosis or mania with methylphenidate use. RESULTS: Among 1,374 case subjects and 2,748 control subjects, the odds of psychosis and mania were increased for individuals with past-month prescription amphetamine use compared with no use (adjusted odds ratio=2.68, 95% CI=1.90-3.77). A dose-response relationship was observed; high doses of amphetamines (>30 mg dextroamphetamine equivalents) were associated with 5.28-fold increased odds of psychosis or mania. Past-month methylphenidate use was not associated with increased odds of psychosis or mania compared with no use (adjusted odds ratio=0.91, 95% CI=0.54-1.55). CONCLUSIONS: Although use of hospitalized control subjects excludes individuals with less severe disease, leading to selection bias, the study results suggest that caution should be exercised when prescribing high doses of amphetamines, with regular screening for symptoms of psychosis or mania.
引用
- Moran LV, Skinner JP, Shinn AK, et al. Risk of Incident Psychosis and Mania With Prescription Amphetamines. Am J Psychiatry. 2024. PMID: 39262211. doi:10.1176/appi.ajp.20230329
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。